Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceFRA:HBI0 53 OCF Yield % is 1.91 as of Aug. 24, 2026, which is 59% below its 10-year median of 4.65. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Harvard Bioscience ranks better than 51.12% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Harvard Bioscience's OCF Yield % or its related term are showing as below:
FRA:HBI0'
s OCF Yield % Range Over the Past 10 Years
Min: -2.48 Med: 4.65 Max: 50.59
Current: 1.91
During the past 13 years, the highest OCF Yield % of Harvard Bioscience was 50.59%. The lowest was -2.48%. And the median was 4.65%.
FRA:HBI0's OCF Yield % is ranked better than 51.12% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:HBI0: 1.91
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Harvard Bioscience OCF Yield % Related Terms
Harvard Bioscience OCF Yield % Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs RVP, MLSS, ZJYL: OCF Yield % Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a OCF Yield % of 1.91 as of Aug. 24, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Harvard Bioscience and its competitors. This is 59% below median its historical median of 4.65. According to the industry distribution chart, Harvard Bioscience ranks #415 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 48.9%.
Is Harvard Bioscience's OCF Yield % too high?
Harvard Bioscience's current OCF Yield % of 1.91 is 59% below median its 10-year median of 4.65. The Medical Devices & Instruments industry median OCF Yield % is 1.63. Harvard Bioscience's value of 1.91 is 17.2% above this industry median. Based on the distribution chart, Harvard Bioscience ranks #415 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's OCF Yield % compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #415 out of 849 companies for OCF Yield %. This puts Harvard Bioscience in the upper half of its industry. The industry median OCF Yield % is 1.63. Harvard Bioscience's value of 1.91 is 17.2% above this benchmark. While the company's 10-year median is 4.65 vs. the industry median of 1.63, Harvard Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.63, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current OCF Yield % of 1.91 is 17.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current OCF Yield % is 1.91, which is 59% below median its own 10-year median of 4.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current OCF Yield % of 1.91. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current OCF Yield % is 1.91, which is 59% below median its 10-year median of 4.65 and 17.2% above the Medical Devices & Instruments industry median of 1.63. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current OCF Yield % is 1.91 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
OCF Yield %: 1.91 (59% below median its 10-year median of 4.65)
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 17.2% above the Medical Devices & Instruments median (#415 of 849)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
